Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
| A ustedes/SKU | Disponibilidad | Precio |
|---|---|---|
5 mg | Póngase en contacto con nuestro Servicio de Atención al Cliente para disponibilidad | 79,40 € 67,49 € |
25 mg | Póngase en contacto con nuestro Servicio de Atención al Cliente para disponibilidad | 322,00 € |
Acerca de este artículo
Fórmula empírica (notación de Hill):
C35H38N4O6 · xHCl
Número CAS:
Peso molecular:
610.70 (free base basis)
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated
67,49 €
Precio de catálogo79,40 €Ahorre 15 %Promoción solo por Internet
Póngase en contacto con nuestro Servicio de Atención al Cliente para disponibilidad
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleassay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: 2 mg/mL, clear (warmed)
storage temp.
2-8°C
Biochem/physiol Actions
Dihydropyridine class calcium channel blocker (CCB) that exerits its antihypertensive activity via targeting both L-type and T-type calcium channels.
Manidipine is a dihydropyridine class calcium channel blocker (CCB) that exerits its antihypertensive activity via targeting both L-type and T-type calcium channels. In contrary to other dihydropyridines and non-dihydropyridines that mainly act as L-type CCBs, Manidipine diminishes glomerular pressure and, consequently, albumin excretion via its action against T-type channels of efferent arterioles in addition to promoting afferent arteriole dilation by blocking L-type channels. Clinically, Manidipine is as effective in lowering blood pressure as other dihydropyridines, while only Manidipine significantly reduces albuminuria and insulin resistance with less adverse effects. In obese and hypertensive individuals, Manidipine is more effective than Lercanidipine in reducing insulin resistance, while Nifedipine treatment is reported to increase insulin desensitisation.
1 of 1
Este artículo | |||
|---|---|---|---|
| form powder | form powder | form powder | form powder |
| assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay ≥98% | assay ≥98% (HPLC) |
| storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C |
| storage condition desiccated | storage condition desiccated | storage condition - | storage condition desiccated, protect from light |
| solubility DMSO: 2 mg/mL, clear (warmed) | solubility DMSO: ≥20 mg/mL | solubility DMSO: ~1 mg/mL, 0.1 M NaOH: insoluble, H2O: slightly soluble, methanol: soluble | solubility - |
| color white to beige | color yellow | color yellow | color yellow |
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - STOT SE 3
target_organs
Central nervous system
Clase de almacenamiento
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.




